• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

    4/8/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email

    - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months -

    - Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR -

    - Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 –

    NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced Cohort 3 data from the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).

    "The remarkable results from Cohort 3 of the ongoing Phase 2 trial reinforce the potential of SLS009 to transform outcomes for these heavily pretreated AML patients," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "Not only have we observed unprecedented survival benefits, but the high response rate underscores the therapy's efficacy profile. The data reveal that relapsed or refractory to venetoclax-based regimens patients receiving 30 mg BIW achieved a mOS of 8.8 months, far surpassing the historical benchmark of 2.5 months. Additionally, the therapy demonstrated a 67% ORR in patients with AML-MRC and 46% in all evaluable patients, significantly exceeding the targeted 20% ORR. With responses seen across different genetic mutations, this approach could be transformational for many underserved patients. We are continuing to explore SLS009's potential in expansion cohorts to further validate its potential to address critical unmet medical needs."

    Patients Characteristics:

    • 14 relapsed and refractory AML patients who previously failed venetoclax-based therapies were enrolled and treated with SLS009 and venetoclax/azacitidine in Cohort 3.
      • 10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia-related cytogenetics).
        • 4 of those patients had myelomonocytic phenotype (M4 per FAB classification). The myelomonocytic phenotype has been shown to exhibit inferior responses to venetoclax-based therapies. It is thought to depend more on the MCL1 anti-apoptotic protein than on the BCL2 anti-apoptotic protein.
        • In terms of specific mutations, 6 patients had ASXL1, 5 had RUNX1 and 3 had TP53.
    • The median age was 71 (range 35-89 years).
    • The median number of prior failed therapy was 1 (range 1-6).
    • 13/14 patients were evaluable for efficacy.
    • All patients had adverse risk cytogenetics per ELN 2022.

    Key Results from Cohort 3:

    • The median overall survival (mOS) for all patients in Cohort 3 was 8.8 months, while the mOS in AML MRC patients reached 8.9 months.
    • The overall response rate (ORR) in all evaluable patients was 46% in all Cohort 3 patients and 67% in AML-MRC patients, far exceeding the targeted ORR of 20%.
      • In the subgroup of patients with myelomonocytic AML, 75% of patients responded (3 out of 4).
    • Among patients with mutation ASXL1, 4/6 (67%) responded; among those with RUNX1 3/5 (60%) responded, and among those with TP53 1/3 (33%) responded. In addition, there were 3 patients with adverse karyotypes and 1 responded.
    • SLS009 was well-tolerated with no new safety signals observed to date as the regimen remains safe in additional patients enrolled to date.
    • Phase 2 trial continues in expansion cohorts 4 and 5, in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations and cytogenic changes other than ASXL1 (cohort 5).

    The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg. In the 60 mg dose cohort patients were treated at either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include two additional cohorts, one with ASXL1 mutated AML patients and one with patients with myelodysplasia-related molecular abnormalities other than ASXL1. The target response rate at the optimal dose level is 20% with a target median survival of at least 3 months. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrial.gov identifier NCT04588922.

    About SELLAS Life Sciences Group, Inc.

    SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as "plan," "expect," "anticipate," "may," "might," "will," "should," "project," "believe," "estimate," "predict," "potential," "intend," or "continue" and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption "Risk Factors" in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

    Investor Contact

    Bruce Mackle

    Managing Director

    LifeSci Advisors, LLC

    [email protected]



    Primary Logo

    Get the next $SLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in TP53 mutated Acute Myeloid Leukemia (AML) cells are being presented in a poster session at the American Association for Cancer Research (AACR) taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. Patients with TP53–mutated AML continue to face extremely poor outcomes, even with intensive chemotherapy or the addition of stem cell transplantation. Precl

      4/28/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois. Poster presentation details: Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 P

      4/23/25 10:23:46 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

      - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR - - Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a br

      4/8/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    See more
    • SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs

      NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality. He joins the Company's executive leadership team and is responsible for developing and executing regulatory strategies. Elnatan has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology, and hematological diseases. His career spans over 25

      1/5/23 8:30:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

      NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the Company has appointed Robert Francomano as Chief Commercial Officer, effective immediately. Mr. Francomano brings significant and broad biopharmaceutical commercial leadership to SELLAS, including experience building and managing oncology product brands through all stages of commercialization, most recently as Chief Commercial Officer at Stemline Therapeutics until the completion and integration of its acquisition by

      3/14/22 7:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.

      DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      4/23/25 4:32:18 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.

      DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      4/23/25 4:30:48 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      3/20/25 4:07:39 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Burns John Thomas was granted 194,300 shares, increasing direct ownership by 185% to 299,062 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:56 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Stergiou Angelos M. was granted 500,900 shares, increasing direct ownership by 140% to 859,032 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:30 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scheinberg David A was granted 12,500 shares, increasing direct ownership by 118% to 23,082 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:08 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

      7/21/21 11:28:03 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital initiated coverage on Solaris Resources with a new price target

      RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

      6/21/21 6:52:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      11/8/24 8:33:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

      SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/7/24 3:01:47 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/16/21 10:08:07 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Financials

    Live finance-specific insights

    See more
    • SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

      NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

      9/8/22 8:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

      NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

      11/12/21 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

      Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

      8/12/21 4:22:52 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care